We are so proud of Dr. Jeff Infante, former Tennessee Oncology physician and key investigator for the Drug Development Unit at Sarah Cannon Research

Dr. Infante is now Global Head of Oncology Early Development and Transitional Research for Janssen Pharmaceutical Company of Johnson & Johnson. In his role he leads a team of physicians and scientists from around the world that design new cancer treatments and develop new cancer drugs. Dr. Infante returned to Tennessee Oncology last year to film […]

Read More

Dr Schleicher, Dr Dickson Discuss New Roles at Tennessee Oncology

Watch the video HERE. Stephen Schleicher, MD, MBA, and Natalie Dickson, MD, discuss their new roles as chief medical officer (CMO) and chief strategy officer (CSO), respectively, at Tennessee Oncology. Tennessee Oncology announced new leadership roles for medical oncologist Stephen Schleicher, MD, MBA, and Natalie Dickson, MD, a medical oncologist/hematologist who most recently served as […]

Read More

“The pace at which new therapies are moving brings hope that all blood cancer patients in the future will have great options for treatment.” – William Donnellan, M.D.

Written by William Donnellan, M.D. After going virtual last year, the annual American Society of Hematology (ASH) meeting was back in person this past December in Atlanta, Georgia. At the annual ASH meeting, oncologists and researchers from all over the world come together to present the latest and greatest research in the field of blood […]

Read More

Tennessee Oncology Appoints Dr. Stephen Schleicher as Chief Medical Officer and Promotes Dr. Natalie Dickson to President and Chief Strategy Officer

Nashville, Tennessee – January 3, 2022 – Tennessee Oncology, one of the largest providers of oncology care in the country, announced today that Stephen Schleicher, MD, MBA has been appointed Chief Medical Officer (CMO) effective January 1, 2022. Natalie Dickson, MD, President and CMO, will remain in her role as president of the company while […]

Read More